Freeline Therapeutics
Latest round
- Series C
Last raised
- Jun 2020
Total raised
- $201M
Investors
- 9
About Freeline Therapeutics
Freeline Therapeutics Limited, founded in 2015 in Stevenage, UK, specializes in gene therapy to address chronic and genetic conditions.05 each. The current CEO is Michael Parini, while Fran Molloy is noted as the founder, with a history that is not disclosed here.Freeline Therapeutics is engaged in the development of gene therapies targeting chronic conditions. Their pipeline includes investigational products like FLT201 for Gaucher disease and a therapy for GBA1-linked Parkinson’s disease. These therapies are designed to change disease progression and are primarily aimed at patients with genetic disorders and neurodegenerative diseases.Freeline Therapeutics plans to launch new products in the near future, targeting the expansion of their gene therapy pipeline. They aim to enter additional markets beyond North America and Europe, although specific regions have not been detailed.
Who invested in Freeline Therapeutics
9 investors across 5 rounds
See all investors in Freeline Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Freeline Therapeutics
Who invested in Freeline Therapeutics?
Freeline Therapeutics has 9 investors on record across 5 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Freeline Therapeutics raised?
Freeline Therapeutics has raised 5 venture rounds. Sign up free to see how much each round raised and the total.
When did Freeline Therapeutics last raise money?
Freeline Therapeutics's most recent round on record is a Series C, in Jun 2020.
What does Freeline Therapeutics do?
Freeline Therapeutics Limited, founded in 2015 in Stevenage, UK, specializes in gene therapy to address chronic and genetic conditions.
Where is Freeline Therapeutics headquartered?
Freeline Therapeutics is headquartered in Stevenage, UK.
Which VCs invest in companies like Freeline Therapeutics?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Generation Investment Management back biotechnology companies at Freeline Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like Freeline Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.